Mr Matthew Shaw


MA(oxon)BM BCh MD FRCS(Urol)

GMC number: 4431101

Practising since: 1997



Consultation times

  • Monday - PM
  • Overview
Book online today Enquire now

Or call us on

0300 1311421


Mr Shaw offers services in most areas of Urological practice, offering an opinion across a range of problems. He specialises in prostate assessment, prostate surgery and complex renal stone surgery using the latest minimally invasive techniques. He is a high volume prostate surgeon using medicine-based and endoscopic management techniques such as holmium laser enucleation of the prostate (HoLEP), transurethral resection of the prostate (TURP) and the minimally invasive technique, Rezum. Mr Shaw is a leading kidney stone surgeon who performs a range of laser-assisted minimally invasive techniques, together with percutaneous (through a skin puncture) surgery and non-invasive external shockwave lithotripsy.

Mr Shaw graduated from the University of Oxford (Oriel College) before completing a Urology research fellowship at The James Whitcomb Riley Children’s Hospital, Indiana University, USA. His Doctorate was performed in the development of the obstructed bladder, a topic relevant to both adults and children. He received his specialist Urology training in the North East of England and was appointed Consultant Urological Surgeon in 2009.

Mr Shaw has worked with the National Institute for Health and Care Excellence in the creation of National quality standards for the management of male urinary symptoms together with advising on the role of metallic ureteric stents and prostate biopsy techniques used in the diagnosis of prostate cancer. He has a particular interest in surgical innovation and research. He has introduced several minimally-invasive surgical procedures to the region, including HoLEP and the prostate steam treatment, Rezum. He is widely published in the International Medical Literature, with publications & presentations relating to the development of the obstructed bladder, stone surgery and ureteric stricture management. He is currently Principal Investigator on the NIHR-sponsored PETS trial, looking at factors affecting thromboembolism in surgery.

Mr Shaw also works at Wansbeck General Hospital, Ashington where he treats male and female bladder problems, prostate disease (benign and malignant), penile and scrotal problems, kidney stones and incontinence.

Mr Shaw spends his spare time outdoors with his family, both in the countryside and his garden. He loves cycling, running, gardening and keeps Japanese Koi carp.

Special interests

Male and female lower urinary tract symptoms
Male bladder outflow surgery including holmium laser enucleation of the prostate (HoLEP) 
Kidney stone diagnosis, management and surgery, including laser treatment
Inguinoscrotal surgery for Hydrocele and epididymal cyst

Personal interests

Mountain biking

Languages spoken


Treatments and tests offered by Mr Matthew Shaw at Nuffield Health

  • Holmium laser enucleation of the prostate (HoLEP)
  • Prostate resection (TURP)
  • Percutaneous nephrolithotomy

Locations Mr Matthew Shaw works with

Related experience


Current Principal Investigator (Newcastle) for NIHR PETS Trial. Examining the benefit of graduated compression stockings in the prevention of thromboembolism in low risk surgical patients. 2023
Infection after ureteroscopy for ureteric stones BJUI 2023, 131(1): 109-115
Impact of COVID-19 on the management and outcomes of ureteric stones in the UK. BJUI 2023, 131: 82-89
Post ureteroscopy infections are linked to a pre-operative dwell time over 2 months J Clin Med 2022, 11(2): 310
An update on endoluminal management of ureteric stricture disease. Urology News Endourology Focus 2022: 12-14
Prostate cancer diagnosis: Biopsy approaches. Urological Cancer 2022, 12: 141-168
A machine learning predictive model for post ureteroscopy urosepsis J Clin Med 2021, 10(17): 388
Urolithiasis. Urology at a glance 2017
Lower urinary tract symptoms in men. Quality standard document CG97 NICE. 2010, revised 2015
The safety and efficacy of PCNL for treatment of paediatric urolithiasis. Ann R Coll Surg Engl 2012, 94(8): 588-92
The influence of high-grade and low-grade histological sub-classification of G2 pT1 transitional cell carcinoma of the bladder. Br J Med & Surg Urol 2011, 4(4): 152-157
Many more publications can be found on my PubMeb bibliography:



  • Royal College of Surgeons of England
  • British Association of Urological Surgeons
  • British Association of Urological Surgeons - Section of Endo-Urology

Other posts held

  • Consultant Urological Surgeon, Freeman Hospital, Newcastle Upon Tyne
  • Honorary Consultant urological Surgeon, Northumbria Healthcare NHS Trust

Insurers Mr Matthew Shaw works with

Mr Matthew Shaw works with the following private medical insurance providers:

  • Aetna
  • Allianz
  • Freedom Health
  • Healix
  • Healthcare RM
  • InterGlobal
  • PHC
  • Police Mutual
  • SecureHealth
  • Simplyhealth
  • Standard Life
  • The Exeter Friendly
  • Tri-Care
  • Universal Provident
  • WPA
  • Bupa
  • AXA Health


Mr Matthew Shaw does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Mr Matthew Shaw does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Mr Matthew Shaw does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.